Shield Therapeutics: providing solutions for unmet medical needs
Shield is a privately held specialty pharmaceutical company with two clinical-stage mineral-medicine assets – ST10 & PT20 – which are each being developed to treat areas of unmet medical need:
- ST10 is being developed as a novel oral therapy for the treatment of iron deficiency
- PT20 is being developed to treat hyperphosphataemia associated with end-stage renal disease
Each asset is utilising simplified regulatory pathways to provide near-term premium pricing opportunities.
The company’s strategy is validated as we are well funded having raised ~$34m from founders, private, strategic and institutional investors.
Our goal is to deliver a virtuous circle of value enhancement for our key stakeholders.